Insurance, HSA and FSA: paying for GLP-1 weight loss

TLDR. Most commercial insurance now covers Wegovy, Zepbound, and other GLP-1s for obesity. Coverage is uneven across plans. Prior authorization is required at almost every plan and roughly 30 to 40 percent of initial PAs are denied. HSA and FSA dollars can pay for the medication and the membership when prescribed for a covered condition, reducing effective cost by your marginal tax rate (typically 22 to 32 percent). Medicare Part D does not cover anti-obesity medications under a statutory exclusion, except for Wegovy when prescribed for cardiovascular risk reduction in established CVD patients.

The insurance landscape for GLP-1 weight loss has changed materially in 2026. Most large commercial plans now cover Wegovy and Zepbound for obesity (BMI ≥30, or BMI ≥27 with comorbidity). Medicaid coverage varies by state. Medicare still does not cover GLP-1s for weight loss alone, only for diabetes.

The catch: coverage in theory and coverage in practice are different things. Prior authorization, step therapy, formulary tiers and quantity limits all reduce the gap between "my plan covers it" and "I can afford it next month."

This post walks through how to figure out your actual out-of-pocket cost before you commit to a program.

Step 1: Check your formulary

Every insurance plan publishes a formulary, the list of drugs it covers, organized into tiers. Each tier has a different copay structure.

For GLP-1 weight loss, you are looking for:

• Wegovy (semaglutide for obesity)
• Zepbound (tirzepatide for obesity)
• Saxenda (liraglutide for obesity, older and less popular)

The formulary will list these as Tier 1 (lowest copay, ~$10-$25), Tier 2 ($35-$60), Tier 3 ($75-$150) or Specialty Tier ($150-$500 or coinsurance %). They might also be listed as "not covered" with no tier.

Practical move: log into your insurance portal, search "Wegovy" or "Zepbound" in the formulary tool. The tier tells you the rough copay. If the tool says "Prior Authorization Required," that is normal, see step 2.

Step 2: Understand prior authorization

Prior authorization (PA) is your insurance plan's gate to confirm the drug is medically appropriate for your specific case. For GLP-1 weight loss, the PA usually requires:

• BMI ≥30, or BMI ≥27 with at least one obesity-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
• Documentation that you have tried and failed lifestyle changes (diet, exercise) for a defined period
• Sometimes: a referral from a physician, lab work showing certain values or step therapy through cheaper medications first

The PA is approved by your insurance plan, not the prescriber. The prescriber submits the PA paperwork; the plan reviews it; the answer is yes, no or a request for more information.

Realistic timeline: 3-14 business days for an initial PA decision. Appeals add another 4-6 weeks if the first answer is no.

Programs that handle PA well: PlushCare, WeightWatchers Clinic, Calibrate, Noom Med. These are explicitly designed around insurance navigation. Their value proposition disappears for cash-pay patients.

Programs that don't focus on PA: Mochi, Hims, Ro. These are cash-pay specialists; insurance is secondary or routed back to the patient to handle.

Step 3: Calculate your post-PA out-of-pocket

Once PA is approved, your monthly cost is:

(Pharmacy retail price) − (Plan's negotiated price) + (Your tier copay) − (Manufacturer savings card) = Your monthly out-of-pocket

Concretely, for Wegovy on a typical commercial PPO with PA approved:

• Retail price: ~$1,300/mo
• Plan negotiated: ~$700/mo
• Tier 3 copay: $75-$150/mo
• Novo Wegovy Savings Card (commercial only): up to $225/mo off, capped
• Realistic out-of-pocket: $0-$50/mo

For Zepbound on the same plan:

• Retail price: ~$1,100/mo
• Plan negotiated: ~$650/mo
• Tier 3 copay: $75-$150/mo
• Lilly Zepbound Savings Card (commercial only): up to $463 off first month then up to $150/mo
• Realistic out-of-pocket: $25-$150/mo

Critical caveat: manufacturer savings cards do not stack with government insurance. If you are on Medicare, Medicaid, Tricare or VA, the savings card is not available to you and the formulary likely does not cover GLP-1s for weight loss anyway.

Step 4: HSA and FSA eligibility

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) let you pay for qualified medical expenses with pre-tax dollars.

For GLP-1 weight loss:

• The medication itself is HSA/FSA eligible. Wegovy and Zepbound copays count. Cash-pay GLP-1 prescriptions count.
• Telehealth membership fees are usually HSA/FSA eligible. The IRS allows medical expense reimbursement for "amounts paid for the diagnosis, cure, mitigation, treatment or prevention of disease." A weight-loss telehealth membership for medical obesity treatment qualifies.
• Compounded GLP-1 medications are HSA/FSA eligible when prescribed for a medical condition, same as branded.

The functional benefit: if you are in a 22% federal tax bracket plus state, your HSA-paid GLP-1 effectively costs you 25-35% less than cash-pay because the dollars come from pre-tax income.

Programs that explicitly accept HSA/FSA: Calibrate, Noom Med, WeightWatchers Clinic. Most others will provide an itemized receipt you can submit for FSA reimbursement.

Step 5: Compare insurance-routed vs cash-pay totals

Once you have the PA-approved out-of-pocket and the cash-pay all-in, the comparison is direct.

For most insured patients on commercial plans with GLP-1 coverage, insurance-routed wins:

• Wegovy via Calibrate (insurance + savings card): ~$199/mo + ~$50 medication = $249/mo all-in
• Wegovy via Mochi (cash-pay compounded): $178/mo all-in
• Wegovy via Hims (cash-pay branded): $299/mo all-in

For patients without GLP-1 coverage on their plan, or with high-deductible plans where the deductible has not been met, cash-pay specialists win:

• Mochi at $178/mo flat
• Hims at $199/mo flat
• Compounded paths via NovoCare/LillyDirect at $149-$299/mo

The decision rule: if you have commercial insurance with explicit GLP-1 coverage for obesity, run prior authorization and pay the copay. If you do not, pick a cash-pay specialist and stop trying to make insurance work.

The most expensive path is signing up for an insurance-navigation program (Calibrate, WeightWatchers Clinic) and discovering at month two that your plan does not cover the medication. You pay the program fee and the cash medication price simultaneously. Confirm coverage before committing to a program built around it.

For a ranked list of the 10 GLP-1 telehealth programs that accept insurance, with what each one costs with coverage and how each one bills your plan, see our GLP-1 telehealth that takes insurance: the 10 programs guide.

Frequently asked questions

Does my commercial insurance cover Wegovy or Zepbound?

Most commercial plans do, with prior authorization. The PA criteria converge on BMI of 30 or higher (or BMI 27 to 29.9 with a qualifying comorbidity), documented lifestyle modification over 6 months, and no contraindication. About 60 to 70 percent of initial PAs approve. Check your plan's formulary and search 'Wegovy' or 'Zepbound' to confirm tier and PA status.

Can I use HSA or FSA dollars for GLP-1 medication?

Yes, when prescribed for a covered medical condition (obesity, type 2 diabetes, cardiovascular risk). The medication, membership fees, and visit fees all qualify as eligible expenses. At a 30 percent marginal tax rate, paying through HSA reduces the effective cost by 30 percent. Keep itemized receipts in case of audit.

Does Medicare cover Wegovy or Zepbound for weight loss?

No. Medicare Part D has a statutory exclusion for anti-obesity medications under the Medicare Modernization Act of 2003. Two narrow exceptions exist: Wegovy is covered for cardiovascular risk reduction in patients with established CVD (a 2024 indication after the SELECT trial), and Ozempic and Mounjaro are covered for type 2 diabetes under different criteria.

What is my actual copay after PA approval?

Most commercial plans land at $25 to $150 per month for tier 2 or tier 3 obesity medications after PA. Manufacturer copay cards from Novo Nordisk (Wegovy) and Lilly (Zepbound) can reduce that further, sometimes to $25/mo for commercial patients. Copay cards do not stack with government insurance.

What if my PA is denied?

Roughly half of denied PAs are reversed on appeal when the prescriber attaches the missing clinical documentation. The most common denial reasons are insufficient lifestyle documentation, missing comorbidity codes, and step-therapy failure documentation. See our appeal-letter library for plan-specific templates.